Breaking News Instant updates and real-time market news.

T

AT&T

$30.33

0.77 (2.60%)

, CMCSA

Comcast

$35.79

1.16 (3.35%)

16:36
01/06/19
01/06
16:36
01/06/19
16:36

Box Office Battle: 'Aquaman' wins weekend again with $31M

AT&T (T) subsidiary Warner Bros' "Aquaman" stayed atop the chart in its third weekend with $30.7M for a North American total of $259.7M and a global tally of $940.7M. Directed by James Wan, "Aquaman" stars Jason Momoa in the titular role alongside Amber Heard, Willem Dafoe, Patrick Wilson and Dolph Lundgren. The film earned an A- CinemaScore and sports a 64% Rotten Tomatoes score. BOX OFFICE RUNNERS-UP: Sony's (SNE) "Escape Room" placed number two in its debut weekend with $18M. Behind it was Disney's (DIS) musical "Mary Poppins Returns," earning $15.8M in its third outing for a domestic cume of $138.7M. Sony's "Spider-Man: Into the Spider-Verse" placed number four with an estimated $13M. Rounding out the top five, Viacom (VIAB) subsidiary Paramount's "Bumblebee" grossed an estimated $12.8M from 3,597 locations. Other publicly traded companies in filmmaking include Comcast (CMCSA), 21st Century Fox's (FOX, FOXA) and Lionsgate's (LGF.A, LGF.B).

T

AT&T

$30.33

0.77 (2.60%)

CMCSA

Comcast

$35.79

1.16 (3.35%)

CMCSK

Comcast

$0.00

(0.00%)

SNE

Sony

$49.28

2.38 (5.07%)

FOX

21st Century Fox

$47.77

0.57 (1.21%)

FOXA

21st Century Fox

$48.07

0.59 (1.24%)

LGF.A

Lionsgate

$17.39

1.05 (6.43%)

DIS

Disney

$109.63

3.34 (3.14%)

VIAB

Viacom

$26.88

0.49 (1.86%)

VIA

Viacom

$29.83

0.58 (1.98%)

  • 07

    Jan

  • 08

    Jan

  • 23

    Jan

  • 23

    Jan

  • 30

    Jan

  • 05

    Feb

  • 25

    Feb

  • 03

    Mar

  • 20

    Mar

T AT&T
$30.33

0.77 (2.60%)

01/02/19
BOFA
01/02/19
NO CHANGE
BOFA
Top 10 US Ideas for Q1 2019 at BofA/Merrill
BofA/Merrill's Alpha Generation Research team introduced its latest Top 10 US Ideas for Q1 2019. The list consists of 9 Buys that are Cigna (CI), Disney (DIS), Equinix (EQIX), Honeywell (HON), Lockheed Martin (LMT), Marvell (MRVL), Procter & Gamble (PG), AT&T (T), and Tapestry (TPR) and 1 Underperform rating which is Campbell Soup (CPB).
12/11/18
12/11/18
UPGRADE

On The Fly: Top five analyst upgrades
Catch up on today's top five analyst upgrades with this list compiled by The Fly: 1. AT&T (T) upgraded to Buy from Neutral at Citi with analyst Michael Rollins saying he expects AT&T to further benefit from the "measured" promotional environment in wireless, while improving its competitive position from FirstNet and the marketing of its network enhancements, branded 5G Evolution. 2. Sanofi (SNY) upgraded to Buy from Hold at Jefferies with analyst Peter Welford saying he believes European large-cap pharmaceuticals are entering a period of sustained earnings momentum which should justify valuations above the historic average for the sector. 3. Total (TOT) upgraded to Buy from Neutral at BofA/Merrill. 4. Zynga (ZNGA) upgraded to Outperform from Neutral at Macquarie. 5. Allstate (ALL) upgraded to Hold from Sell at Edward Jones. This list is just a portion of The Fly's full analyst coverage. To see The Fly's full Street Research coverage, click here.
12/11/18
MSCO
12/11/18
NO CHANGE
Target $37
MSCO
Overweight
AT&T likely to raise dividend despite deleveraging goals, says Morgan Stanley
Morgan Stanley analyst Simon Flannery said he expects AT&T to raise its quarterly dividend by 1c to 51c from 50c per share as early as this Friday, which would be in-line with its timing last year. He would view such an increase, which would not be that notable normally but takes on added significance due to the company's high leverage and desire to delever, as a signal of confidence in the recent 2019 business and financial outlook, Flannery tells investors. He maintains an Overweight rating and $37 price target on AT&T shares.
12/11/18
SBSH
12/11/18
UPGRADE
Target $34
SBSH
Buy
Citi upgrades AT&T to Buy with shares down 23% year-to-date
Citi analyst Michael Rollins upgraded AT&T to Buy from Neutral with an unchanged price target of $34. The stock closed yesterday down 24c to $29.91. The analyst expects AT&T to further benefit from the "measured" promotional environment in wireless, while improving its competitive position from FirstNet and the marketing of its network enhancements, branded 5G Evolution. Further, the company has "several levers" to manage free cash flow and support its net debt deleveraging goals for 2019, Rollins tells investors in a research note. In addition, the analyst believes the stock's 23% decline year-to-date provides a better risk/reward scenario. AT&T trades at a price-to-earnings ratio of about eight times the analyst's revised 2019 outlook and at a dividend yield of about 6.7%. He sees a buying opportunity at current share levels.
CMCSA Comcast
$35.79

1.16 (3.35%)

12/07/18
WOLF
12/07/18
INITIATION
Target $48
WOLF
Outperform
Comcast Comcast initiated with an Outperform at Wolfe Research
Wolfe Research initiated Comcast with an Outperform rating and $48 price target.
12/03/18
JPMS
12/03/18
DOWNGRADE
Target $62
JPMS
Neutral
JPMorgan downgrades Verizon to Neutral after 17% rally, prefers AT&T
JPMorgan analyst Philip Cusick downgraded Verizon Communications (VZ) to Neutral from Overweight with an unchanged price target of $62. The analyst says that as much as he likes Verizon's "consistent and improving execution," the combination of a new management team and reporting lines with the stock's 17% year-to-date increase make the risk/reward less compelling than peers AT&T (T) and Comcast (CMCSA). Cusick, however, still sees the stock increasing 2.7% to his $62 target in the next year along with the 4.0% dividend yield.
11/13/18
LEHM
11/13/18
INITIATION
Target $44
LEHM
Overweight
Comcast reinstated with an Overweight at Barclays
Barclays analyst Kannan Venkateshwar reinstated coverage of Comcast with an Overweight rating and $44 price target. Negativity around the Sky deal seems overstated, Venkateshwar tells investors in a research note. There is "little doubt" that Comcast overpaid for Sky using any conventional valuation metric, says the analyst. However, he also believes looking at transaction multiples "essentially assumes a static strategic state for the combination, which is unlikely." The analyst thinks Comcast's guidance on synergies is likely to prove conservative.
11/08/18
11/08/18
INITIATION

On The Fly: Top analyst initiations
Catch up on today's top analyst initiations with this list compiled by The Fly: 1. Stanley Black & Decker (SWK) initiated with a Hold at Deutsche Bank. 2. Comcast (CMCSA) resumed with an Overweight at Morgan Stanley while Amarin (AMRN) and Immunomedics (IMMU) were assumed with a Buy at the firm. 3. Broadcom (AVGO) resumed with a Buy at Deutsche Bank and reinstated with an Overweight at JPMorgan. This list is just a portion of The Fly's analyst coverage. To see The Fly's full Street Research coverage, click here.
CMCSK Comcast
$0.00

(0.00%)

11/08/18
MSCO
11/08/18
INITIATION
Target $46
MSCO
Overweight
Comcast resumed with an Overweight at Morgan Stanley
Morgan Stanley analyst Benjamin Swinburne resumed coverage of Comcast (CMCSA) with an Overweight rating and $46 price target, stating that while the burden of proof is on the company to successfully execute its Sky (SKYAY) acquisition, the stock's multiple has compressed even though his expectation for Comcast's consolidated growth outlook has not materially changed. In the near-term, Sky will be accretive to that growth rate, Swinburne added. He also said that Comcast "remains first and foremost a US cable business," and he sees broadband as a secular growth driver with a long-term runway.
10/30/18
MSCO
10/30/18
NO CHANGE
Target $95
MSCO
Overweight
WWE shares 'on sale' after pullback, says Morgan Stanley
Morgan Stanley analyst Benjamin Swinburne noted that WWE (WWE) shares are down by over 30% this month, which he sees as a "rare opportunity" to buy shares of a company that he sees having both highly visible earnings growth and growing intellectual property value. He attributes the rapid selloff primarily to a broader market rotation out of risk assets due to rising interest rates and concerns over achieving long-term growth, but he thinks this "does not make sense" given that WWE's EBITDA opportunity "is not a decade away, but rather a year away," Swinburne tells investors. Two contracts underwritten by Comcast (CMCSA) and Fox (FOXA) drive the bulk of its earnings growth and its financial outlook has no immediate exposure to ratings or cord-cutting, Swinburne added. While he trimmed his price target on WWE shares to $95 from $105 after bumping up his investment expectations for 2019, the analyst maintains an Overweight rating on the stock.
10/26/18
10/26/18
UPGRADE
Target $44

Outperform
Credit Suisse upgrades Comcast to Outperform on increased confidence in growth
As previously reported, Credit Suisse analyst Douglas Mitchelson upgraded Comcast to Outperform from Neutral, stating that he has increased confidence in its growth outlook given renewed momentum in broadband net adds, pricing upside, the deteriorating competitive positioning of satellite, wireless investment likely having peaked, and NBCU being well positioned. Additionally, he sees the potential for capital intensity to moderate meaningfully over time. Mitchelson increased his estimates above consensus and raised his price target on Comcast shares to $44 from $36.
SNE Sony
$49.28

2.38 (5.07%)

10/22/18
MSCO
10/22/18
NO CHANGE
MSCO
Morgan Stanley says publishers in 'win-win' situation as consoles move to cloud
Morgan Stanley analyst Brian Nowak sees changes coming to the $53B global console gaming market as the business model transitions toward subscription pricing and cloud delivery. The transition will lead to 2% CAGR console gaming revenue growth from 2017-2025, but gross profit growth accelerating to 6%, Nowak estimates. He believes game publishers such as Activision Blizzard (ATVI), Electronic Arts (EA) and Take-Two (TTWO) will likely need to partner and bundle content to drive material consumer adoption, but he sees them being in a "win-win" position, because even if the console makers or other aggregators drive the cloud transition, the leading publishers can still benefit from expansion in the player base, Nowak tells investors. While console players Microsoft (MSFT) and Sony (SNE) have the most at risk from these changes, they are also positioned best to build and grow game subscription services, Nowak added.
12/06/18
CHLM
12/06/18
INITIATION
Target $5
CHLM
Buy
Telaria initiated with a Buy at Craig-Hallum
Craig-Hallum analyst Jason Kreyer started coverage of Telaria (TLRA) with a Buy rating and $5 price target. The analyst notes that the company's partnerships with over-the-top streaming providers such as Hulu, Sling (DISH), Sony's (SNE) VUE, Fox (FOXA), A&E, and FuboTV generated about 20% of total revenue last year and he projects it will grow to nearly 60% by 2020. As consumers continue to pivot toward over-the-top subscriptions, Telaria benefits from its agnostic platform that partners with a variety of publishers to monetize video ad content, Kreyer contends.
11/30/18
11/30/18
UPGRADE

On The Fly: Top five analyst upgrades
Catch up on today's top five analyst upgrades with this list compiled by The Fly: 1. UDR, Inc. (UDR) upgraded to Buy from Hold at Jefferies with analyst Omotayo Okusanya saying the company's above average net operating income growth and development pipeline position it to be one of the best funds from operations growth stories in 2019. 2. Under Armour (UAA) upgraded to Market Perform from Underperform at Wells Fargo with analyst Tom Nikic saying after two-plus years of "choppy operating performance," the worst is now over for Under Armour. 3. WWE (WWE) upgraded to Overweight from Neutral at JPMorgan with analyst David Karnovsky saying shares are off 26% from peak levels reached at the end of September and now trade at 14.5 times estimated 2020 adjusted OIBDA. 4. Volaris (VLRS) upgraded to Hold from Reduce at HSBC. 5. Sony (SNE) upgraded to Buy from Neutral at Citi. This list is just a portion of The Fly's full analyst coverage. To see The Fly's full Street Research coverage, click here.
11/30/18
SBSH
11/30/18
UPGRADE
SBSH
Buy
Sony upgraded to Buy from Neutral at Citi
Citi analyst Kota Ezawa upgraded Sony to Buy with an increased price target of 9,000 yen.
FOX 21st Century Fox
$47.77

0.57 (1.21%)

10/15/18
MSCO
10/15/18
NO CHANGE
Target $135
MSCO
Overweight
Disney shares appear 'compelling' at current levels, says Morgan Stanley
Morgan Stanley analyst Benjamin Swinburne believes Disney (DIS) shares appear "compelling" at a current valuation of under 13x "core" FY20 pro forma EPS given the company's opportunity to maximize the potential of the acquired Fox (FOXA) assets and scale a direct-to-consumer business. He attributes investor reluctance to own Disney shares to uncertainty about its ability to simultaneously execute on a large acquisition, launch a global direct-to-consumer business and grow, but Swinburne sees this "complexity discount" as an opportunity, he tells investors. He maintains an Overweight rating on Disney shares with a $135 price target.
11/08/18
MSCO
11/08/18
NO CHANGE
Target $54
MSCO
Overweight
Morgan Stanley raises 'New Fox' estimates after 21st Century Fox report
Morgan Stanley analyst Benjamin Swinburne said 21st Century Fox's Q1 results reinforced his conviction in his Overweight view, as he believes its strong distribution and ad sales results in the U.S. underscore Fox's pricing power. Following the quarterly report, Swinburne raised his estimates for "New Fox" and increased his price target on 21st Century Fox shares to $54 from $53 based on his value of $13 per share for "New Fox" and $41 per share for "RemainCo." The analyst also noted that Fox's international cable networks came in below his expectations, adding that he believes Disney's (DIS) acquisition of Fox's content production assets and Star India, along with gaining a majority stake in Hulu, are the primary growth drivers.
FOXA 21st Century Fox
$48.07

0.59 (1.24%)

12/07/18
WOLF
12/07/18
INITIATION
Target $16
WOLF
Outperform
21st Century Fox initiated with an Outperform at Wolfe Research
Wolfe Research initiated 21st Century Fox with an Outperform and $16 price target.
11/29/18
IMPC
11/29/18
NO CHANGE
Target $32
IMPC
Outperform
Disney sale of sports networks should revalue MSG Networks, says Imperial
MSG Networks (MSGN), as the only pure-play regional sports networks security publicly traded, is "vastly under-covered and under-appreciated," Imperial Capital analyst David Miller tells investors in a research note. Disney (DIS) is selling off the Fox Regional Sports Networks, which the company must do per Department of Justice decree issued on June 27, adds the analyst. He believes that as the closest pure-play comparable to these networks, the terminal value of the transaction should lead to a revaluation of MSG Networks in the public markets. Miller keeps an Outperform rating on MSG Networks with a $32 price target.
11/28/18
GSCO
11/28/18
DOWNGRADE
GSCO
Neutral
Genting Malaysia downgraded to Neutral from Buy at Goldman Sachs
Goldman Sachs analyst Simon Cheung downgraded Genting Malaysia Bhd. (GMALF) to Neutral after the company sued Disney (DIS) and 21st Century Fox (FOXA) for pulling out of an agreement to sponsor a Fox World theme park outside Kuala Lumpur. Genting is seeking more than $1B in damages and claims Disney doesn't want to be associated with its gambling business. Goldman now sees uncertainty with the outdoor theme park and steps to the sidelines with respect to Genting Malaysia shares.
LGF.A Lionsgate
$17.39

1.05 (6.43%)

12/18/18
DBAB
12/18/18
UPGRADE
Target $29
DBAB
Buy
Lionsgate upgraded to Buy from Hold at Deutsche Bank
Deutsche Bank analyst Bryan Kraft upgraded Lionsgate (LGF.A) to Buy and raised his price target for the shares to $29 from $26.
12/13/18
EVER
12/13/18
NO CHANGE
Target $26
EVER
Outperform
Lionsgate price target cut to $26, removed from SMID Cap list at Evercore ISI
Evercore ISI analyst David Joyce lowered his price target for Lionsgate to $26 from $31, while reiterating an Outperform rating on the shares given a likely write-off of a recent film release that underperformed expectations and the de-risking in the broader market. The analyst also removed the stock from its firm's SMID Cap Core list as it appears it will take some time for Lionsgate to execute on various fronts in order to prove that Adjusted OIBDA growth is again achievable. Nonetheless, Joyce believes shares have been oversold and are attractive levels for investors with a longer-term view.
12/19/18
RILY
12/19/18
NO CHANGE
Target $20
RILY
Buy
Lionsgate price target lowered to $20 from $27 at B. Riley FBR
B. Riley FBR analyst Barton Crockett lowered his price target for Lionsgate to $20 from $27 while retaining a Buy rating on the shares.
12/18/18
12/18/18
UPGRADE

Fly Intel: Top five analyst upgrades
Catch up on today's top five analyst upgrades with this list compiled by The Fly: 1. Lionsgate (LGF.A, LGF.B, LGF) upgraded to Buy from Hold at Deutsche Bank. 2. Norfolk Southern (NSC) upgraded to Overweight from Neutral at JPMorgan with analyst Brian Ossenbeck saying he estimates $600M of potential productivity gains based on his analysis and points out that he has long favored Eastern rails as a region. 3. China Life Insurance (LFC) upgraded to Neutral from Sell at Goldman Sachs. 4. Ametek (AME) and Fortive (FTV) were assumed at Overweight from Equal Weight at Morgan Stanley. 5. Host Hotels (HST) upgraded to Outperform from In Line at Evercore ISI, while Public Storage (PSA) was upgraded to In Line from Underperform. This list is just a portion of The Fly's full analyst coverage. To see The Fly's full Street Research coverage, click here.
DIS Disney
$109.63

3.34 (3.14%)

12/14/18
NEED
12/14/18
NO CHANGE
Target $100
NEED
Buy
Electronic Arts price target lowered to $100 from $150 at Needham
Needham analyst Laura Martin lowered her price target on Electronic Arts (EA) to $100 given the company's less inspiring game release slate in FY20 relative to FY19, noting that the margins on the Star Wars title expected next year are lower than this year's Battlefield because of Disney (DIS) royalties. The analyst also attributes the lower target to the market repricing of stocks "valued at over 4-times enterprise value to sales". Martin is keeping her Buy rating on Electronic Arts given the ownership of its own IP assets, loyalty of "super-fans", lower risk based on its dependence on title "sequels", and the under-40 age demographic of its target market. The analyst adds that while the company does not have a "Sports game creation problem", the same may not be said about action/adventure game creation.
12/07/18
NEED
12/07/18
NO CHANGE
NEED
Hold
Disney may need to lower FY19 estimates, says Needham
Needham analyst Laura Martin kept her Hold rating on Disney, warning that the company may need to lower its FY19 earnings guidance at its April investor meeting. The analyst cites the company's growing costs around "technology, content and marketing investments" in OTT services such as ESPN+ and Disney+, along with earnings dilution from the acquisition of 21st Century Fox. Martin also lowers her FY19 EPS view to $7.13 from $7.35 based on higher ESPN+ investments, rising programming costs related to college playoff games, and lower Studio segment revenue from tough comps related to last year's Thor, Coco, and Star Wars films.
12/07/18
WOLF
12/07/18
INITIATION
Target $147
WOLF
Outperform
Disney initiated with an Outperform at Wolfe Research
Wolfe Research initiated Disney with an Outperform and $147price target.
VIAB Viacom
$26.88

0.49 (1.86%)

12/27/18
LOOP
12/27/18
NO CHANGE
Target $59
LOOP
Buy
CBS risk-reward 'very favorable', says Loop Capital
Loop Capital analyst Alan Gould kept his Buy rating on CBS (CBS), saying the stock carries the "most favorable risk/reward of media companies" in his coverage universe. The analyst notes that the uncertainty around the company's CEO role, discussions around NFL rights, and the possibility of a Viacom (VIAB) merger have driven down CBS stock price, lowing his price target to $59 from $68 to reflect the volatility of the shares. Gould contends however that CBS valuation is now "extraordinarily attractive", adding that his new price target still implies a 36% upside potential.
12/28/18
RILY
12/28/18
NO CHANGE
Target $30
RILY
Buy
Viacom price target lowered to $30 from $39 at B. Riley FBR
B. Riley FBR analyst Barton Crockett lowered his price target for Viacom (VIAB) to $30 from $39 after adjusting his estimates. The analyst keeps a Buy rating on the shares.
01/02/19
SPHN
01/02/19
UPGRADE
Target $58
SPHN
Overweight
CBS upgraded to Overweight from Equal Weight at Stephens
Stephens analyst Kyle Evans upgraded CBS to Overweight from Equal Weight as he believes investor sentiment is poised to improve on the name in 2019 and that the company can continue to post solid results driven by underlying unit growth and stronger pricing. While the threat of a potential Viacom (VIAB) transaction remains, Evans also sees "a decent chance" CBS will become an acquisition target itself as the OTT and streaming video markets become increasingly competitive, he tells investors. Evans keeps a $58 price target on CBS shares.
01/02/19
BRRR
01/02/19
UPGRADE
Target $35
BRRR
Outperform
Viacom upgraded to Outperform from Market Perform at Barrington
Barrington analyst James Goss upgraded Viacom (VIAB) to Outperform with a price target of $35. The analyst believes the fundamental progress for Viacom in its own turnaround efforts is not at all reflected in the stock's current trading levels. His upgrade reflects the company's efforts at improving the operational performance of its two main business segments.
VIA Viacom
$29.83

0.58 (1.98%)

11/28/18
IMPC
11/28/18
NO CHANGE
Target $30
IMPC
In-Line
Viacom estimates lowered on 'Instant Family' opening at Imperial Capital
Imperial Capital analyst David Miller lowered his Q1 core earnings per share estimate for Viacom to $1.02 from $1.18 to reflect the weaker than expected theatrical receipts for "Instant Family." It appears as if the move will be a short run, Miller tells investors in a research note partially titled "So Where is the Turnaround?" The analyst says he has not seen any evidence of a turnaround thus far for Viacom, at least theatrically. He keeps an In-Line rating on the shares with a $30 price target.
11/29/18
11/29/18
INITIATION

On The Fly: Top five analyst upgrades
Catch up on today's top five analyst initiations with this list compiled by The Fly: 1. Pluralsight (PS) initiated with an Outperform at Baird. 2. Expedia (EXPE) initiated with a Market Perform at Telsey Advisory. 3. Energy Transfer LP (ET) initiated with a Buy at Citi. 4. Skyline (SKY) initiated with a Neutral at Credit Suisse. 5. CBS (CBS) and Viacom (VIAB, VIA) were reinstated with a Neutral at Goldman Sachs. This list is just a portion of The Fly's analyst coverage. To see The Fly's full Street Research coverage, click here.

TODAY'S FREE FLY STORIES

PEBO

Peoples Bancorp

$31.57

-0.11 (-0.35%)

07:11
01/22/19
01/22
07:11
01/22/19
07:11
Hot Stocks
Peoples Bancorp reports Q4 net interest margin 3.77% vs. 3.68% sequentially »

Compared to 3.63% for the…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 22

    Jan

AXGN

AxoGen

$16.00

0.64 (4.17%)

07:10
01/22/19
01/22
07:10
01/22/19
07:10
Hot Stocks
AxoGen appoints Eric Sandberg CCO »

AxoGen (AXGN) announced…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

PEBO

Peoples Bancorp

$31.57

-0.11 (-0.35%)

07:10
01/22/19
01/22
07:10
01/22/19
07:10
Earnings
Peoples Bancorp reports Q4 EPS 71c, consensus 67c »

Earnings per diluted…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 22

    Jan

CTSO

CytoSorbents

$7.66

0.04 (0.52%)

07:09
01/22/19
01/22
07:09
01/22/19
07:09
Hot Stocks
CytoSorbents expands partnership with Fresenius Medical Care to Korea and Mexico »

CytoSorbents announced…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

WB

Weibo

$60.80

2.57 (4.41%)

07:09
01/22/19
01/22
07:09
01/22/19
07:09
Downgrade
Weibo rating change  »

Weibo downgraded to…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

DRNA

Dicerna

$10.76

-0.395 (-3.54%)

07:08
01/22/19
01/22
07:08
01/22/19
07:08
Upgrade
Dicerna rating change  »

Dicerna upgraded to Buy…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

TRV

Travelers

$123.97

1.03 (0.84%)

07:07
01/22/19
01/22
07:07
01/22/19
07:07
Hot Stocks
Travelers reports Q4 return on equity 10.9% »

Reports Q4 core return on…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 22

    Jan

VYGR

Voyager Therapeutics

$8.27

-0.22 (-2.59%)

, RHHBY

Roche

$0.00

(0.00%)

07:07
01/22/19
01/22
07:07
01/22/19
07:07
Hot Stocks
Voyager Therapeutics names Robert Hesslein as general counsel »

Voyager Therapeutics…

VYGR

Voyager Therapeutics

$8.27

-0.22 (-2.59%)

RHHBY

Roche

$0.00

(0.00%)

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 28

    Jan

  • 01

    Feb

  • 18

    Mar

CAPR

Capricor Therapeutics

$0.62

-0.007 (-1.11%)

07:07
01/22/19
01/22
07:07
01/22/19
07:07
Hot Stocks
Capricor Therapeutics announces outcome of FDA meeting for CAP-1002 »

Capricor Therapeutics…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

AUPH

Aurinia Pharmaceuticals

$7.54

0.11 (1.48%)

07:07
01/22/19
01/22
07:07
01/22/19
07:07
Hot Stocks
Breaking Hot Stocks news story on Aurinia Pharmaceuticals »

Aurinia Pharmaceuticals…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 22

    Jan

REXR

Rexford Industrial

$32.00

0.225 (0.71%)

07:07
01/22/19
01/22
07:07
01/22/19
07:07
Hot Stocks
Rexford Industrial acquires two industrial properties for $27.6M »

Rexford Industrial Realty…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

MDT

Medtronic

$87.31

-0.29 (-0.33%)

07:06
01/22/19
01/22
07:06
01/22/19
07:06
Hot Stocks
Medtronic announces new data shared on IN.PACT Admiral DCB »

Medtronic announced new…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 27

    Jan

  • 18

    May

  • 28

    May

BG

Bunge

$52.95

0.745 (1.43%)

07:06
01/22/19
01/22
07:06
01/22/19
07:06
Hot Stocks
Bunge says Lupo, Bachrach, Boilini won't stand for re-election to board »

As part of Bunge's…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

AUPH

Aurinia Pharmaceuticals

$7.54

0.11 (1.48%)

07:05
01/22/19
01/22
07:05
01/22/19
07:05
Hot Stocks
Aurinia says VOS demonstrates statistically superior efficacy versus Restasis »

Aurinia Pharmaceuticals…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 22

    Jan

07:05
01/22/19
01/22
07:05
01/22/19
07:05
General news
Global stock markets under pressure after gloomy IMF report. »

Global stock markets…

BG

Bunge

$52.95

0.745 (1.43%)

07:04
01/22/19
01/22
07:04
01/22/19
07:04
Hot Stocks
Bunge sees FY18 total segment adjusted EBIT below previously disclosed range »

The company provided an…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

IPGP

IPG Photonics

$132.54

3.37 (2.61%)

07:04
01/22/19
01/22
07:04
01/22/19
07:04
Hot Stocks
IPG Photonics to acquire Padtec SND »

IPG Photonics announced…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

CNC

Centene

$126.64

1.37 (1.09%)

07:04
01/22/19
01/22
07:04
01/22/19
07:04
Hot Stocks
Centene subsidiary selected by Arizona's Department of Corrections »

Centene announced that…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 05

    Feb

  • 28

    May

QURE

uniQure

$31.29

-0.02 (-0.06%)

07:04
01/22/19
01/22
07:04
01/22/19
07:04
Hot Stocks
uniQure announces FDA clearance of AMT-130 NDA in Huntington's disease »

uniQure N.V. announced…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

CNCE

Concert Pharmaceuticals

$14.21

-0.065 (-0.46%)

07:04
01/22/19
01/22
07:04
01/22/19
07:04
Hot Stocks
Concert completes enrollment of 12 mg cohort in CTP-543 Phase 2a trial »

Concert Pharmaceuticals…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 29

    Jan

  • 30

    Jan

  • 12

    Feb

  • 13

    Feb

RCKT

Rocket Pharmaceuticals

$16.00

0.23 (1.46%)

07:03
01/22/19
01/22
07:03
01/22/19
07:03
Hot Stocks
Rocket Pharmaceuticals announces FDA clearance of IND application for RP-A501 »

Rocket Pharmaceuticals…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

PSTI

Pluristem

$1.12

(0.00%)

07:03
01/22/19
01/22
07:03
01/22/19
07:03
Hot Stocks
Pluristem to collaborate with IDF in treatment of burn injuries »

Pluristem Therapeutics…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

TLRY

Tilray

$77.14

-6.17 (-7.41%)

07:02
01/22/19
01/22
07:02
01/22/19
07:02
Hot Stocks
Tilray to acquire Natura Naturals for up to C$70M »

Tilray announced it has…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

BG

Bunge

$52.95

0.745 (1.43%)

, CAG

Conagra Brands

$21.58

0.34 (1.60%)

07:02
01/22/19
01/22
07:02
01/22/19
07:02
Hot Stocks
Bunge names Gregory Heckman as acting CEO »

Bunge (BG) announced that…

BG

Bunge

$52.95

0.745 (1.43%)

CAG

Conagra Brands

$21.58

0.34 (1.60%)

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 22

    Jan

CGEN

Compugen

$3.18

0.07 (2.25%)

07:02
01/22/19
01/22
07:02
01/22/19
07:02
Hot Stocks
Compugen announces publication of preclinical data on PVRIG »

Compugen announced the…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

Get Full Fly Access

Breaking market intelligence sent straight to you
Our team of experts analyze every news story and filter out the noise to deliver real-time market moving news.
Up-to-date information on important industry events
Get real-time updates on events that are moving the market—from conferences and calls to syndicate announcements.
News focused on the companies in your portfolio
Create up to 12 portfolios with 150 stocks each, and see how active they are in market news.